Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People

Registration is not required.

Date: Thursday, August 12, 2021

Time: 2:00 PM – 3:00 PM ET

A few minutes before the webinar begins, please click the link below to join:
https://www.zoomgov.com/j/1612254638?pwd=SmNaNlJEUWt3YWdBMGtNRjhxRlZ1UT09external icon

Webinar ID: 161 225 4638

Passcode: 980771

Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 669 216 1590 or +1 551 285 1373

One-tap mobile: US: +16692545252,,1612254638#,,,,*980771#  or +16468287666,,1612254638#,,,,*980771#

International numbers available: https://www.zoomgov.com/u/adQOV17URbexternal icon

Activity-specific Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

1. Describe FDA’s role in issuing EUA for Casirivimab/Imdevimab.
2. Outline the process for ordering and distributing Casirivimab/Imdevimab.
3. Discuss findings of studies on mAbs for COVID-19 (published or in unpublished pre-print).
4. Describe the National Institutes of Health (NIH) COVID-19 Treatment Guidelines’ Panel’s recommendations on using monoclonal antibodies to treat non-hospitalized patients with mild-to-moderate COVID-19.
5. List options for post-exposure prophylaxis use of Casirivimab/Imdevimab.

COCA Call Objectives

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC’s role in the topic covered during the presentation.
3. Describe the topic’s implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

None At This Time

To receive continuing education (CE) for WC2922-081221 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars –Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People, Thursday, August 12, 2021, please visit TCEO and follow these 9 Simple Steps by Monday, September 13, 2021.

To receive continuing education (CE) for WD2922-081221 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People, Thursday, August 12, 2021,(Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, September 14, 2021 and Wednesday, September 14, 2023.

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity provides 1.0 contact hour.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-21-226-L04-P and enduring JA4008229-0000-21-227-H04-P course category.

This activity has been designated as Knowledge-Based.

DISCLOSURE:
In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias.

The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use except parts of the presentation will focus on monoclonal antibodies that are not FDA approved but are FDA authorized under Emergency Use Authorization (EUA) and there will be mention of COVID-19 serology tests that have FDA EUA and have been used for post-vaccine serology determinations for clinical trials and research studies (as noted in published or pre-print articles).

CDC did not accept commercial support for this continuing education activity.

• Physicians
• Nurses
• Pharmacists
• Veterinarians
• Physician Assistants
• Health Educators
• Other Clinicians

System requirements to use Zoomexternal iconexternal icon

• Contact Information:coca@cdc.gov
• Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
• Method of Participation:You may participate in the educational activity by viewing the program information above.